User: Guest  Login
Document type:
journal article 
Author(s):
Warnke, C; Menge, T; Hartung, HP; Racke, MK; Cravens, PD; Bennett, JL; Frohman, EM; Greenberg, BM; Zamvil, SS; Gold, R; Hemmer, B; Kieseier, BC; Stüve, O 
Title:
Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided? 
Abstract:
Natalizumab (Tysabri) was the first monoclonal antibody approved for the treatment of relapsing forms of multiple sclerosis (MS). After its initial approval, 3 patients undergoing natalizumab therapy in combination with other immunoregulatory and immunosuppressive agents were diagnosed with progressive multifocal leukoencephalopathy (PML). The agent was later reapproved and its use restricted to monotherapy in patients with relapsing forms of MS. Since reapproval in 2006, additional cases of PML...    »
 
Journal title abbreviation:
Arch Neurol 
Year:
2010 
Journal volume:
67 
Journal issue:
Pages contribution:
923-30 
Language:
eng 
Print-ISSN:
0003-9942 
TUM Institution:
Neurologische Klinik und Poliklinik